Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.

Abstract: The present invention relates to methods of making peptides or a mixture of peptides that can be used to pulse dendritic cells against the oncofetal antigen/immature laminin receptor protein (OFA/iLRP). More specifically, dendritic cells can be derived from a range of different sources that can direct the immune system to attack specific antigens. Once sensitized, either ex vivo, in vivo or in vitro, the dendritic cells will aid an individual's own immune system to protect against or treat all types of OFA/iLRP-related cancer. The peptides may also be used for detection, diagnosis and monitoring, and treatment of a OFA/iLRP-related cancer.

Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.